Researchers from the University of Minnesota School of Medicine obtained an investment from the Parsemus Foundation to publish studies on metformin, a generally used diabetes drug, which will be marketed internationally as a cheap generic drug for coVID-19 prevention and remedy.
To avoid delays in the COVID-19 pandemic, the California-based Parsemus Foundation is investing the application of new experimental drugs (INDs) from the University of Minnesota to the Food and Drug Administration (FDA) to launch a multicenter randomized controlled clinical trial of metformin use as a COVID-19 remedy and prevention approach The U of MS Medical School study team , led by co-principal researchers Carolyn Bramante, MD, MPH, department of medicine, and Christopher Tignanelli, MD of the Department of Surgery, filed the IND application on August 12 in the coming weeks to ensure greater investment.
Epidemiological knowledge of several studies around the world, not just ours, a tendency or effect of metformin on the prevention of hospitalizations and deaths by COVID-19 and there is a mechanism of action: metformin has a little known history as antiviral, in addition to its relief in blood sugar and its anti-inflammatory effect. Among the proposed routes are TNF and mTOR. But, a randomized clinical trial is needed to ensure that the arrangement is in fact cause and effect. “
“Several observational studies in the United States and around the world have shown an arrangement between outpatient use of metformin and relief of mortality and COVID-19 hospitalizations,” Bramante said. “The most recent articles (one of which is still publicly available) were written in detailed databases that took into account the frame’s mass index and glucose framework point (Hemoglobin A1C). 19, adding its inflammation-reducing effects and potentially also its ability to inhibit mTOR, a protein that helps the virus grow. “
Metformin, known to many under the logo called Fortamet or Glucophage, is used as a diabetes medication to lower glucose levels, with unusual secondary advantages of loss of appetite and weight loss. The effects of previous studies provided Bramante’s team with an explanation as to why metformin is a promising method for COVID-19 remedy and prevention, adding initial knowledge of a co-directed observational study through Bramante and Tignanelli.
The team reviewed unitedHealthcare’s anonymized knowledge and found that women who already took metformin and who had been diagnosed with COVID-19 had a reduced death threat of about 25%. Preliminary knowledge of some other observational examination of patients with nonalcoholic fatty liver disease, co-directed through Bramante and Tignanelli, showed that the remedy for metabolic disease, adding metformin intake, was linked to a lower probability of being hospitalized by COVID-19. The effects are consistent with the effects of observational studies in China and France and the University of Alabama.
When approving the IND application, the objective of the clinical trial will be twofold: to definitively investigate whether or not metformin saves you SARS-CoV-2 infection and whether or not it can save you serious coVID-19 illnesses and hospitalization in the exclusive exams you designed will also help determine the duration of metformin needed to discharge those benefits. Since metformin is already widely used and available, its use for COVID-19 can begin as soon as positive clinical effects are achieved and replace global popular care to save health and disease at an early stage, similar to recent end effects on dexamethasone for complex diseases.
CDC forecasts expect 1,300 to 5,500 new COVID-19 hospitalizations in line with the day through October 12 in the United States alone. This means that a remedy that reduces hospitalizations by approximately 50-60%, as evidenced by observation data, can potentially save you thousands of hospitalizations every day in the United States. With generics available for less than $4 according to the month of brands around the world, metformin has the merit that it can be used without delay and economically worldwide. Metformin is also safe for everyone (children, pregnant women, adults of all ages), as long as they do not have significant renal, hepatic or central impairment.
Although the Parsemus Foundation was the initial funding, it is too small to fund the full test.
“We are proud to join the University of Minnesota School of Medicine to offer an initial investment to launch the metformin trial. The team has carried out immediate and definitive checks and a position has control sites throughout the country in “Start” conditions, said the Foundation’s trustee, Elaine Lissner. “All the puzzle pieces are there, just combine them with other sponsors to start the study. “
University of Minnesota School of Medicine
News-Medical. net – An AZoNetwork site
Owned and operated by AZoNetwork, © 2000-2020